Document is current
Any future updates will be listed below
-
Authors
Bektas, Delal
De Maria, Lucio
Graepel, Stephen
Lanzino, Giuseppe
Flemming, Kelly D.
- License Information
-
More Information
Article History
Received: 25 January 2025
Revised: 24 March 2025
Accepted: 13 April 2025
First Online: 24 April 2025
Declarations
:
: All patients provided informed consent, and IRB approved the study (IRB number: 18-007392). Clinical Trial Number: Not applicable.
: The authors declare no competing interests.
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Kelly D. Flemming has consulted for Ovid therapeutics, Blueprint Orphan, and Recursion pharmaceutical. Giuseppe Lanzino has consulted for Nested Knowledge and Superior Medical Editors.
